{
  "ctfidf_model": {
    "bm25_weighting": false,
    "reduce_frequent_words": false
  },
  "vectorizer_model": {
    "params": {
      "analyzer": "word",
      "binary": false,
      "decode_error": "strict",
      "encoding": "utf-8",
      "input": "content",
      "lowercase": true,
      "max_df": 1.0,
      "max_features": null,
      "min_df": 5,
      "ngram_range": [
        1,
        3
      ],
      "stop_words": "english",
      "strip_accents": null,
      "token_pattern": "(?u)\\b\\w\\w+\\b",
      "vocabulary": null
    },
    "vocab": {
      "studies": 385,
      "dmt": 116,
      "progression": 319,
      "work": 422,
      "best": 42,
      "neurodegeneration": 259,
      "need": 256,
      "new": 262,
      "prevent": 312,
      "dmts": 117,
      "spms": 381,
      "disability": 105,
      "early": 122,
      "time": 396,
      "treatment": 402,
      "long": 210,
      "term": 392,
      "results": 351,
      "showed": 371,
      "patients": 283,
      "group": 165,
      "lower": 213,
      "edss": 137,
      "course": 85,
      "follow": 153,
      "increased": 184,
      "rate": 324,
      "significantly": 375,
      "different": 103,
      "treated": 401,
      "disease": 110,
      "did": 102,
      "later": 196,
      "non": 269,
      "higher": 173,
      "effect": 138,
      "progressive": 321,
      "phase": 295,
      "does": 118,
      "stage": 383,
      "ectrims2022": 127,
      "multiple": 242,
      "sclerosis": 358,
      "news": 266,
      "today": 397,
      "years": 426,
      "tomorrow": 399,
      "11": 2,
      "better": 43,
      "age": 27,
      "ms": 225,
      "brain": 48,
      "don": 119,
      "going": 162,
      "effective": 139,
      "currently": 90,
      "symptoms": 390,
      "rrms": 354,
      "following": 154,
      "months": 223,
      "cns": 67,
      "present": 305,
      "receiving": 330,
      "community": 74,
      "2022": 7,
      "ectrims": 123,
      "congress": 78,
      "october": 274,
      "26": 8,
      "28": 11,
      "amsterdam": 28,
      "netherlands": 258,
      "trial": 406,
      "presented": 308,
      "view": 415,
      "relapses": 338,
      "continues": 83,
      "impact": 178,
      "people": 286,
      "optica": 278,
      "disorder": 115,
      "nmosd": 268,
      "multiplesclerosis": 248,
      "learn": 200,
      "based": 38,
      "cognitive": 69,
      "therapy": 395,
      "reduced": 333,
      "compared": 75,
      "research": 347,
      "shows": 373,
      "reducing": 335,
      "activity": 25,
      "relapsing": 339,
      "forms": 155,
      "msnews": 236,
      "msawareness": 233,
      "msresearch": 239,
      "neurotwitter": 261,
      "lead": 198,
      "levels": 203,
      "help": 170,
      "mssociety": 241,
      "dr": 121,
      "bruce": 52,
      "discusses": 108,
      "presentations": 307,
      "attention": 37,
      "high": 171,
      "efficacy": 141,
      "modifying": 221,
      "therapies": 394,
      "associated": 35,
      "risk": 352,
      "recent": 331,
      "data": 93,
      "suggest": 387,
      "significant": 374,
      "lesions": 202,
      "study": 386,
      "ocrevus": 272,
      "chronic": 63,
      "active": 24,
      "md": 216,
      "center": 57,
      "medical": 219,
      "findings": 151,
      "38th": 13,
      "european": 142,
      "committee": 70,
      "clinical": 65,
      "biomarker": 44,
      "investigational": 190,
      "10": 1,
      "analysis": 29,
      "mri": 224,
      "using": 413,
      "participants": 281,
      "oral": 279,
      "baseline": 39,
      "mean": 217,
      "49": 17,
      "volume": 417,
      "evidence": 146,
      "greater": 164,
      "professor": 317,
      "neurology": 260,
      "university": 410,
      "novel": 270,
      "reduce": 332,
      "activation": 23,
      "related": 342,
      "ongoing": 275,
      "questions": 323,
      "similar": 376,
      "including": 182,
      "important": 179,
      "reports": 346,
      "year": 425,
      "read": 326,
      "poster": 300,
      "cognition": 68,
      "phd": 296,
      "discussed": 107,
      "function": 158,
      "future": 159,
      "abstract": 19,
      "watch": 419,
      "progress": 318,
      "developing": 99,
      "post": 299,
      "relapse": 336,
      "rates": 325,
      "independent": 185,
      "common": 73,
      "lesion": 201,
      "seen": 363,
      "spinal": 379,
      "cord": 84,
      "remitting": 344,
      "measures": 218,
      "daily": 91,
      "free": 157,
      "ata188": 36,
      "pharma": 294,
      "vs": 418,
      "presentation": 306,
      "reduces": 334,
      "antibodies": 33,
      "damage": 92,
      "outcomes": 280,
      "safety": 355,
      "day": 95,
      "key": 192,
      "role": 353,
      "prof": 316,
      "just": 191,
      "dose": 120,
      "really": 329,
      "great": 163,
      "presenting": 310,
      "longitudinal": 212,
      "living": 207,
      "anti": 31,
      "inflammatory": 187,
      "talk": 391,
      "blood": 46,
      "care": 53,
      "like": 205,
      "covid": 86,
      "19": 5,
      "life": 204,
      "severe": 366,
      "increase": 183,
      "meeting": 220,
      "latest": 197,
      "treatments": 405,
      "changes": 61,
      "highlights": 175,
      "working": 423,
      "scientific": 357,
      "field": 150,
      "shared": 368,
      "information": 188,
      "healthcare": 168,
      "advancing": 26,
      "000": 0,
      "12": 3,
      "weeks": 421,
      "benefit": 40,
      "session": 364,
      "sharing": 370,
      "patient": 282,
      "fantastic": 149,
      "oct": 273,
      "events": 145,
      "gavingiovannoni": 160,
      "stop": 384,
      "booth": 47,
      "current": 89,
      "development": 100,
      "potential": 302,
      "presents": 311,
      "13": 4,
      "abstracts": 20,
      "precision": 304,
      "announced": 30,
      "label": 193,
      "value": 414,
      "diagnosis": 101,
      "discussion": 109,
      "factors": 148,
      "leading": 199,
      "condition": 76,
      "27": 10,
      "unique": 409,
      "individuals": 186,
      "cis": 64,
      "sure": 389,
      "check": 62,
      "specific": 378,
      "biomarkers": 45,
      "imaging": 176,
      "insights": 189,
      "improve": 180,
      "brandon_beaber": 49,
      "themsguide": 393,
      "immune": 177,
      "world": 424,
      "monoclonal": 222,
      "benefits": 41,
      "visit": 416,
      "showing": 372,
      "live": 206,
      "ocrelizumab": 271,
      "digital": 104,
      "health": 167,
      "csf": 88,
      "48": 16,
      "cells": 56,
      "30": 12,
      "problems": 315,
      "according": 21,
      "website": 420,
      "source": 377,
      "release": 343,
      "previous": 313,
      "management": 215,
      "bring": 51,
      "scale": 356,
      "20": 6,
      "chain": 59,
      "change": 60,
      "make": 214,
      "hear": 169,
      "develop": 98,
      "share": 367,
      "days": 96,
      "real": 327,
      "experience": 147,
      "practice": 303,
      "cell": 55,
      "diseases": 114,
      "effects": 140,
      "demonstrate": 97,
      "consistent": 81,
      "prior": 314,
      "central": 58,
      "understanding": 408,
      "needs": 257,
      "response": 350,
      "improvement": 181,
      "long term": 211,
      "disability progression": 106,
      "multiple sclerosis": 243,
      "news today": 267,
      "26 28": 9,
      "sclerosis ectrims2022": 360,
      "patients ms": 284,
      "new research": 264,
      "disease activity": 111,
      "forms ms": 156,
      "ms multiplesclerosis": 230,
      "multiplesclerosis msnews": 252,
      "msnews msawareness": 237,
      "msawareness msresearch": 234,
      "msresearch ectrims2022": 240,
      "ectrims2022 ectrims2022": 130,
      "multiplesclerosis ectrims2022": 250,
      "ectrims2022 multiplesclerosis": 132,
      "high efficacy": 172,
      "disease modifying": 112,
      "multiplesclerosis ms": 251,
      "progressive ms": 322,
      "ms new": 231,
      "new data": 263,
      "new study": 265,
      "multiplesclerosis news": 254,
      "sclerosis ms": 361,
      "38th congress": 14,
      "congress european": 79,
      "european committee": 143,
      "committee treatment": 71,
      "treatment research": 403,
      "research multiple": 348,
      "sclerosis ectrims": 359,
      "ectrims 2022": 124,
      "people multiple": 291,
      "today ectrims2022": 398,
      "ectrims2022 people": 134,
      "people ms": 290,
      "relapse rates": 337,
      "ms patients": 232,
      "spinal cord": 380,
      "relapsing remitting": 340,
      "remitting ms": 345,
      "ms ectrims2022": 229,
      "presented ectrims2022": 309,
      "ectrims ectrims2022": 125,
      "ectrims2022 ectrims": 129,
      "ectrims multiplesclerosis": 126,
      "covid 19": 87,
      "ectrims2022 dr": 128,
      "session ectrims2022": 365,
      "clinical trial": 66,
      "ms ectrims": 228,
      "disease progression": 113,
      "people living": 287,
      "living ms": 208,
      "ms disease": 227,
      "ectrims2022 ms": 131,
      "ms community": 226,
      "ectrims2022 poster": 135,
      "poster session": 301,
      "data presented": 94,
      "sclerosis patients": 362,
      "multiple sclerosis ectrims2022": 245,
      "multiplesclerosis msnews msawareness": 253,
      "msnews msawareness msresearch": 238,
      "msawareness msresearch ectrims2022": 235,
      "multiplesclerosis news today": 255,
      "multiple sclerosis ms": 246,
      "38th congress european": 15,
      "congress european committee": 80,
      "european committee treatment": 144,
      "committee treatment research": 72,
      "treatment research multiple": 404,
      "research multiple sclerosis": 349,
      "multiple sclerosis ectrims": 244,
      "people multiple sclerosis": 292,
      "relapsing remitting ms": 341,
      "people living ms": 288,
      "multiple sclerosis patients": 247,
      "having": 166,
      "spoke": 382,
      "positive": 297,
      "50": 18,
      "shares": 369,
      "cd20": 54,
      "highlighting": 174,
      "period": 293,
      "genentech": 161,
      "ectrims22": 136,
      "treat": 400,
      "late": 194,
      "breaking": 50,
      "possible": 298,
      "suggests": 388,
      "approach": 34,
      "onset": 276,
      "used": 412,
      "focused": 152,
      "unmet": 411,
      "trials": 407,
      "confirmed": 77,
      "multiplesclerosis ectrims": 249,
      "anti cd20": 32,
      "living multiplesclerosis": 209,
      "late breaking": 195,
      "onset ms": 277,
      "ectrims2022 new": 133,
      "patients relapsing": 285,
      "people living multiplesclerosis": 289,
      "real world": 328,
      "continued": 82,
      "progression patients": 320,
      "according data": 22
    }
  }
}